ArticleFrontiers in pharmacology2026
Fibroblast growth factor 2 (FGF2) modulates the excitability of brain noradrenergic and serotonergic neurons: possible involvement of FGFR1 and FGFR4 receptors.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fibroblast growth factor 2 (FGF2), in addition to its primary function in the connective tissue, plays also a role in the central nervous system (CNS). Thus, anxiolytic, antidepressant, and pro-addictive properties of this molecule have been reported. Our previous study showed that pro-alcohol consumption effect of FGF2 is mediated, at least in part, via its interaction with the central dopaminergic system. The present study aimed to test the hypothesis that pro-addictive and/or antidepressant-like effects of FGF2 can also be linked with FGF2-noradrenaline and FGF2-serotonin (5-HT) interactions. Methods: Adult male Wistar rats, weighing 250-350 g, were treated with the recombinant FGF2, selective inhibitors of FGFR1 (PD173074), FGFR2 (lirafugratinib), FGFR4 (BLU9931), or corresponding vehicle. The excitability of the noradrenergic neurons of the locus coeruleus (LC) and serotonergic (5-HT) neurons of the dorsal raphe nucleus (DRN) was assessed using the single-unit Results: We found that FGF2 stimulated the burst firing of noradrenergic neurons and inhibited the burst firing of 5-HT neurons. PD173074 decreased the density of the spontaneously active noradrenergic neurons in the locus coeruleus, whereas BLU9931 had a stimulatory effect on the burst activity of 5-HT neurons. Conclusion: The psychoactive effects of the FGF2 might be mediated, at least in part, via its interaction with the central monoaminergic circuits. The FGF2-catecholaminergic interactions are putatively mediated via FGFR1, and FGF2-5-HT-crosstalk-via FGFR4. These two receptors can be thus potential targets for the future CNS drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.